FY2026 EPS Estimates for TSE:MDP Cut by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Leede Financial reduced their FY2026 earnings estimates for Medexus Pharmaceuticals in a research note issued to investors on Friday, November 8th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of $0.22 per share for the year, down from their previous estimate of $0.23. Leede Financial currently has a “Speculative Buy” rating and a $8.25 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.60 EPS.

Other analysts also recently issued reports about the company. Stifel Canada upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd.

Medexus Pharmaceuticals Stock Down 3.4 %

Shares of TSE MDP opened at C$1.96 on Monday. Medexus Pharmaceuticals has a twelve month low of C$1.44 and a twelve month high of C$3.16. The firm has a market cap of C$48.08 million, a PE ratio of 39.20 and a beta of 1.96. The business has a fifty day simple moving average of C$2.53 and a two-hundred day simple moving average of C$2.18.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.